Published on
Jun 13, 2025
Phase III POETYK PsA Trials Show Significant Clinical Benefit with Sotyktu in Psoriatic Arthritis
Key Takeaways Sotyktu Meets Primary Endpoint in POETYK PsA-1 Trial. In the Phase III POETYK PsA-1 trial, 54.2% of patients receiving Sotyktu achieved an ACR20 response at week 16 compared to 34.1% on placebo (p<0.0001), demonstrating significant …
Source:
Applied Clinical Trials
-
Pending
%2c_analyze_by_microscope-Jarun_Ontakrai_8864dd9cfb3b4dff9a913aede7a7c915-620x480.jpg)
